CSE Bulletin: Name Change - Algernon Pharmaceuticals Inc.

CSE Bulletin: Name Change - Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc. has announced a name change to Algernon Health Inc.

Shares will begin trading under the new name and with a new CUSIP number on October 20, 2025.

The symbol will remain the same.

Disclosure documents are available at www.thecse.com.

Please note that all open orders will be cancelled at the end of business on October 17, 2025. Dealers are reminded to re-enter their orders.

_________________________________

Algernon Pharmaceuticals Inc. a annoncé un changement de nom pour Algernon Health Inc.

Les actions commenceront à être négociées sous ce nouveau nom et avec un nouveau numéro CUSIP à compter du 20 octobre 2025.

Le symbole restera le même.

Les documents d'information sont disponibles sur www.thecse.com.

Veuillez noter que tous les ordres ouverts seront annulés à la fin des heures d'ouverture le 17 octobre 2025. Il est rappelé aux courtiers de ressaisir leurs ordres.

Effective Date/ Date Effective : Le 20 OCT 2025
Symbol/ Symbole : AGN
New CUSIP/ Nouveau CUSIP : 01559C 10 6
New ISIN/ Nouveau ISIN : CA 01559C 10 6 8
Old/Vieux CUSIP & ISIN : 01559R400/CA01559R4008

 

If you have any questions or require further information, please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com.

Pour toute question, pour obtenir de l'information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l'adresse: Listings@thecse.com.

News Provided by Newsfile via QuoteMedia

AGN:CNX
The Conversation (0)
Algernon Pharmaceuticals

Algernon Pharmaceuticals

Repurposing Established Drugs to Create New Treatments

Repurposing Established Drugs to Create New Treatments Keep Reading...

Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, is pleased to announce that Algernon's CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company's New DMT Stroke... Keep Reading...

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT "The Spirit Molecule"

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment of stroke focused on AP-188... Keep Reading...

Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company (the "November Warrants"), that were issued on... Keep Reading...

Algernon Pharmaceuticals Provides Reminder on Expiry Date of Accelerated Warrants

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company is pleased to provide a reminder to the market that the common share purchase warrants of the Company that were issued on November 1, 2019... Keep Reading...

Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the " Company " or " Algernon ") a clinical stage pharmaceutical development company, is pleased to announce that the external Data and Safety Monitoring Board ("DSMB") has completed its latest review of the Phase 2b part... Keep Reading...

Latest Press Releases

Related News